Table 2.
Anticoagulant information.
| Not Reversed n = 84 | Reversed n = 186 | p | |
|---|---|---|---|
| Anticoagulation Medication | |||
| Edoxaban | 0 | 1% (1) | 0.002 |
| Apixaban | 15% (13) | 11% (20) | |
| Dabigatran | 1% (1) | 3% (6) | |
| Warfarin | 52% (44) | 73% (135) | |
| Rivaroxaban | 31% (26) | 13% (24) | |
| Anticoagulation Medication Type | |||
| Warfarin | 52% (44) | 73% (135) | 0.001 |
| DOAC | 48% (40) | 27% (51) | |
| Indication for Anticoagulation1 | |||
| A-fib | 64% (54) | 70% (131) | 0.31 |
| DVT or PE | 12% (10) | 15% (27) | 0.56 |
| Mechanical Valve Replacement | 5% (4) | 4% (8) | >0.99 |
| Stroke or CVA | 10% (8) | 5% (10) | 0.21 |
| CAD | 8% (7) | 9% (16) | 0.94 |
| Other | 1% (1) | 3% (5) | 0.44 |
| Bridge Given % Yes (n) | 17% (14) | 48% (90) | <0.001 |
| Anticoagulant Bridge Medication | |||
| Heparin | 1% (1) | 4% (7) | 0.44 |
| Enoxaparin | 15% (13) | 45% (83) | <0.001 |
| Total Bridge Dose (ml) | |||
| Heparin Median (IQR) | 50002 | 5000 (2500, 13500) | N/A |
| Enoxaparin Median (IQR) | 120 (60, 150) | 60 (30, 140) | 0.12 |
| Bridge Timing | |||
| Pre-Op | 0 | 4% (8) | N/A |
| Post-Op | 17% (14) | 46% (86) | <0.001 |
| Time from last dose to surgery (hours) Median (IQR) | 22 (17, 26) | 48 (29, 62) | <0.001 |
Bonferroni-adjusted p = 0.025, DOAC = direct oral anticoagulant, A-fib = atrial fibrillation, VTE = venous thromboembolism, CVA = cerebrovascular accident, CAD = coronary artery disease, Alpha 1 = Alpha 1 antitrypsin deficiency, PVD = peripheral vascular disease. 1 = Patients can have multiple indications for anticoagulant use, 2 = heparin bridge only provided to one patient in the not reversed group.